Preora is focused on commercializing low-cost, minimally invasive and highly sensitive pre-screening tests for several cancers.
Evanston, IL (PRWEB) September 10, 2015
Preora Diagnostics Inc., a privately held medical technology company that will bring low-cost cancer pre-screening tests to primary care physicians in the United States and other select markets worldwide, will present at the AdvaMed 2015 Conference at 11:40am PT on October 7 in San Diego. Preora President and CEO John W. Hart will participate in the “Point-of-Care Diagnostics” panel discussion on the Innovation Showcase Stage in the Exhibit Hall.
AdvaMed 2015 is the leading gathering in North America of global MedTech executives. The AdvaMed trade organization describes the Innovation Showcase as a new and unique program featuring the most promising, innovative and emerging growth MedTech companies.
Last month, the PROPEL Center of the Illinois Biotechnology Organization (iBIO) Institute announced that it is providing a grant to Preora to support its participation in the Innovation Showcase. The PROPEL Center’s news release indicates that Preora is one of only eight Illinois companies to receive a grant to participate in the Innovation Showcase.
About Preora Diagnostics
Preora Diagnostics is a medical technology company focused on commercializing low-cost, minimally invasive and highly sensitive pre-screening tests for several cancers. The tests are simple enough to be performed in a primary care office without any extensive preparation. The pre-screening tests are based on the proprietary Partial Wave Spectroscopy (PWS) nanocytology platform, licensed exclusively by Preora through its parent company (NanoCytomics LLC) and Northwestern University. For more information, visit http://www.PreoraDx.com.